Kasper S, Vecsei P, Richter P, Haack D, Diebold K, Katzinski L
Psychiatric Department, University of Heidelberg, Federal Republic of Germany.
J Neural Transm. 1988;74(3):161-74. doi: 10.1007/BF01244782.
Betamethasone induced cortisol suppressibility was examined in 62 drug free consecutively admitted psychiatric inpatients. Betamethasone was choosen instead of the commonly used dexamethasone, because its double half-life compared to dexamethasone and its higher tissue availability. After a base-line evaluation with blood samples drawn at 8 a.m., 4 p.m., and 11 p.m., 0.5 mg or 1.0 mg betamethasone was given orally at 11 p.m. Postbetamethasone cortisol as well as betamethasone blood levels were then measured at the same time points as on the baseline day. In the groups receiving 1.0 mg betamethasone non-depressed patients had significantly (p less than 0.05) lower postbetamethasone cortisol levels than depressed patients for each time point measured whereas 0.5 mg betamethasone did not differentiate depressed from non-depressed patients. Patients with other depressions like schizoaffective psychosis-depressive subtype- or organic brain syndrome with depressive symptomatology demonstrated similar postbetamethasone cortisol profiles as the group of patients with major depression. Betamethasone plasma concentrations differed significantly (p less than 0.001) with respect to the oral dosage with higher values for the 1.0 mg betamethasone groups.
对62名连续入院且未服用药物的精神科住院患者进行了倍他米松诱导的皮质醇抑制性检查。选择倍他米松而非常用的地塞米松,是因为其半衰期是地塞米松的两倍,且组织利用率更高。在上午8点、下午4点和晚上11点采集血样进行基线评估后,于晚上11点口服0.5毫克或1.0毫克倍他米松。然后在与基线日相同的时间点测量倍他米松给药后的皮质醇水平以及倍他米松血药浓度。在接受1.0毫克倍他米松的组中,在每个测量时间点,非抑郁患者的倍他米松给药后皮质醇水平均显著低于抑郁患者(p<0.05),而0.5毫克倍他米松未能区分抑郁患者和非抑郁患者。患有其他抑郁症的患者,如精神分裂症情感障碍抑郁亚型或伴有抑郁症状的器质性脑综合征患者,其倍他米松给药后的皮质醇水平与重度抑郁症患者组相似。倍他米松血浆浓度因口服剂量不同而有显著差异(p<0.001),1.0毫克倍他米松组的值更高。